CLSN:NSD-Celsion Corporation (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 1.35

Change

-0.06 (-4.26)%

Market Cap

USD 0.12B

Volume

2.84M

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Celsion Corporation, a clinical stage biotechnology company, focuses on the development and commercialization of directed chemotherapies, DNA-mediated immunotherapy, and vaccines. Its lead product candidate is ThermoDox, a liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for the treatment of primary liver cancer. The company is also developing GEN-1, a DNA-based immunotherapeutic product, which is in Phase II clinical trials for the localized treatment of ovarian cancers. Celsion Corporation was founded in 1982 and is based in Lawrenceville, New Jersey.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-04-09 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

+3.07 (+1.46%)

USD54.66B 20.44 15.09
MRNA Moderna, Inc

+7.04 (+5.26%)

USD53.62B N/A N/A
REGN Regeneron Pharmaceuticals, Inc

-1.19 (-0.25%)

USD51.03B 15.61 12.36
ALXN Alexion Pharmaceuticals, Inc

+0.54 (+0.35%)

USD33.96B 56.79 33.32
BGNE BeiGene, Ltd

-6.35 (-2.02%)

USD29.36B N/A N/A
BNTX BioNTech SE

+7.65 (+6.68%)

USD27.29B -99,999.99 N/A
SGEN Seagen Inc

-1.62 (-1.12%)

USD26.58B 43.50 36.12
RPRX Royalty Pharma plc

+0.37 (+0.88%)

USD25.46B 22.60 15.46
GMAB Genmab A/S

+0.58 (+1.73%)

USD21.63B 26.59 3.09
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing CLSN

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 90.14% 95% A 94% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 90.14% 95% A 94% A
Trailing 12 Months  
Capital Gain 36.01% 48% F 35% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 36.01% 48% F 33% F
Trailing 5 Years  
Capital Gain -92.96% 12% F 3% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -92.96% 12% F 3% F
Average Annual (5 Year Horizon)  
Capital Gain -24.80% 8% F 4% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -24.80% 8% F 4% F
Risk Return Profile  
Volatility (Standard Deviation) 54.30% 58% F 29% F
Risk Adjusted Return -45.67% 15% F 8% F
Market Capitalization 0.12B 20% F 23% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 5.88 42% F 31% F
Price / Cash Flow Ratio -7.81 46% F 72% C-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -129.54% 19% F 9% F
Return on Invested Capital -69.30% 33% F 12% F
Return on Assets -30.48% 41% F 12% F
Debt to Equity Ratio 21.14% 41% F 60% D-
Technical Ratios  
Short Ratio 0.14 94% A 90% A-
Short Percent 5.16% 56% F 38% F
Beta 2.04 22% F 13% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.